SCHEMBL4865875

SCHEMBL4865875

O=C(CN1CCN(CC(O)COc2ccccc2F)CC1)NCCc1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
USP2 O75604 1/20 0.48
HTT P42858 1/20 0.48
CYP2D6 P10635 2/20 0.48
CYP1A2 P05177 1/20 0.48
LMNA P02545 1/20 0.47
HRH1 P35367 1/20 0.46
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
HPGD P15428 1/20 0.45
ATF4 P18848 4/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866090 0.92 MEN1 (0.49) MEN1KMT2AUSP2HTTCYP2D6
SCHEMBL4861739 0.90 CYP2D6 (0.58) MEN1KMT2AUSP2HTTCYP2D6
SCHEMBL3827757 0.83 MEN1 (0.63) MEN1KMT2ATDP1HTTLMNA
SCHEMBL3831399 0.83 MEN1 (0.48) MEN1KMT2ATDP1HTTCYP2D6
SCHEMBL4861763 0.83 ABCB1 (0.53) MEN1KMT2ACYP2D6CYP3A4TSHR
SCHEMBL4865613 0.82 TSHR (0.48) MEN1KMT2AUSP2CYP2D6CYP1A2
SCHEMBL4862091 0.81 MEN1 (0.49) MEN1KMT2AUSP2HTTCYP2D6
SCHEMBL4862068 0.80 KCNH2 (0.52) MEN1KMT2AUSP2HTTCYP2D6
SCHEMBL4493648 0.80 HPGD (0.55) MEN1KMT2ATDP1HTTLMNA
SCHEMBL4865295 0.78 NPSR1 (0.55) MEN1KMT2AUSP2HTTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A MEN1 3200/4885KMT2A 3201/4885TDP1 3448/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A MEN1 2899/4885KMT2A 3029/4885TDP1 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.